These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 16938747)

  • 1. Evolution of pulmonary surfactants for the treatment of neonatal respiratory distress syndrome and paediatric lung diseases.
    Mazela J; Merritt TA; Gadzinowski J; Sinha S
    Acta Paediatr; 2006 Sep; 95(9):1036-48. PubMed ID: 16938747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surfactant trials.
    Moya FR; Sinha SK; D'Agostino R
    Pediatrics; 2006 Jan; 117(1):245-7; author reply 247-8. PubMed ID: 16396889
    [No Abstract]   [Full Text] [Related]  

  • 3. Surfactant respiratory therapy using Surfaxin/sinapultide.
    Lal MK; Sinha SK
    Ther Adv Respir Dis; 2008 Oct; 2(5):339-44. PubMed ID: 19124381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome.
    Pfister RH; Soll RF; Wiswell T
    Cochrane Database Syst Rev; 2007 Jul; (3):CD006069. PubMed ID: 17636826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome.
    Pfister RH; Soll RF; Wiswell T
    Cochrane Database Syst Rev; 2007 Oct; (4):CD006069. PubMed ID: 17943881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lucinactant for the prevention of respiratory distress syndrome in premature infants.
    Jordan BK; Donn SM
    Expert Rev Clin Pharmacol; 2013 Mar; 6(2):115-21. PubMed ID: 23473590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary distribution of lucinactant and poractant alfa and their peridosing hemodynamic effects in a preterm lamb model of respiratory distress syndrome.
    Terry MH; Merritt TA; Harding B; Schroeder H; Merrill-Henry J; Mazela J; Gregory TJ; Segal R; Power GG; Blood AB
    Pediatr Res; 2010 Sep; 68(3):193-8. PubMed ID: 20531255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute and sustained effects of lucinactant versus poractant-alpha on pulmonary gas exchange and mechanics in premature lambs with respiratory distress syndrome.
    Gastiasoro-Cuesta E; Alvarez-Diaz FJ; Rey-Santano C; Arnaiz-Renedo A; Loureiro-Gonzalez B; Valls-i-Soler A
    Pediatrics; 2006 Feb; 117(2):295-303. PubMed ID: 16452346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lucinactant: a novel synthetic surfactant for the treatment of respiratory distress syndrome.
    Donn SM
    Expert Opin Investig Drugs; 2005 Mar; 14(3):329-34. PubMed ID: 15833063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lucinactant for the treatment of respiratory distress syndrome in neonates.
    Piehl E; Fernandez-Bustamante A
    Drugs Today (Barc); 2012 Sep; 48(9):587-93. PubMed ID: 23032799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fifth time's the charm?
    Hersher R
    Nat Med; 2012 Feb; 18(2):186. PubMed ID: 22310673
    [No Abstract]   [Full Text] [Related]  

  • 12. Synthetic surfactants: the search goes on.
    Kattwinkel J
    Pediatrics; 2005 Apr; 115(4):1075-6. PubMed ID: 15805389
    [No Abstract]   [Full Text] [Related]  

  • 13. One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials.
    Moya F; Sinha S; Gadzinowski J; D'Agostino R; Segal R; Guardia C; Mazela J; Liu G;
    Pediatrics; 2007 Jun; 119(6):e1361-70. PubMed ID: 17533176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of exogenous pulmonary surfactants on mortality rate in neonatal respiratory distress syndrome: A network meta-analysis of randomized controlled trials.
    Zhang L; Cao HY; Zhao S; Yuan LJ; Han D; Jiang H; Wu S; Wu HM
    Pulm Pharmacol Ther; 2015 Oct; 34():46-54. PubMed ID: 26296793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expanded use of surfactant therapy in newborns.
    Lacaze-Masmonteil T
    Clin Perinatol; 2007 Mar; 34(1):179-89, ix. PubMed ID: 17394937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of artificial surfactant (ALEC) in the prophylaxis of neonatal respiratory distress syndrome.
    Morley CJ
    Eur Respir J Suppl; 1989 Mar; 3():81s-86s. PubMed ID: 2663001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lucinactant approved for respiratory distress syndrome.
    Traynor K
    Am J Health Syst Pharm; 2012 Apr; 69(8):628. PubMed ID: 22472860
    [No Abstract]   [Full Text] [Related]  

  • 18. Fifth time's the charm for infant respiratory distress drug.
    Katsnelson A
    Nat Biotechnol; 2012 May; 30(5):380. PubMed ID: 22565949
    [No Abstract]   [Full Text] [Related]  

  • 19. Exogenous surfactant therapy: newer developments.
    Lacaze-Masmonteil T
    Semin Neonatol; 2003 Dec; 8(6):433-40. PubMed ID: 15001115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Biophysical models in investigations of exogenous surfactant activities on the surface tension and their theurapeutic effectiveness].
    Todorov R; Iordanova A; Georgiev GA; Petkova Kh; Stoimenova E; Georgieva R; Khristova E; Vasiliev Kh; Lalchev Z
    Akush Ginekol (Sofiia); 2007; 46 Suppl 1():29-36. PubMed ID: 18175392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.